Acrivon Therapeutics

Company snapshot

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutati

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Acrivon Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Acrivon Therapeutics.

1. Jun 8, 2026 Clinical update

   ACR-368-201 — Phase 2

2. May 23, 2026 Clinical update

   ACR-368 — Phase 2

3. May 23, 2026 Clinical update

   Gemcitabine — Phase 2

4. May 23, 2026 Clinical update

   ACR-2316 — Phase 1

View all clinical trial activity →

• What is Acrivon Therapeutics?

  Acrivon Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker ACRV. Primary therapeutic focus areas include Endometrial cancer, Specific Advanced Solid Tumors, Endometrial Adenocarcinoma, Head and Neck Squamous Cell Carcinoma. NovaP

• Is Acrivon Therapeutics publicly traded?

  Yes. Acrivon Therapeutics is listed with ticker ACRV on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Acrivon Therapeutics develop or market?

  We link 3 drug profile(s) where Acrivon Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/acrivon-therapeutics#company-drugs.

• What are the latest developments for Acrivon Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Acrivon Therapeutics focus on?

  Acrivon Therapeutics focuses on Endometrial cancer, Specific Advanced Solid Tumors, Endometrial Adenocarcinoma based on our analysis of their pipeline programs and drug development activities.